MICHAEL JOHNSON to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications MICHAEL JOHNSON has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.335
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
Score: 0.130
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
Score: 0.130
-
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol. 2015 Apr; 38(2):165-73.
Score: 0.076